Jason Hoitt has sold stock and made no open-market buys since Jul 2019

Jason Hoitt is a Chief Patient Officer at Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA-based medicines to address the underlying cause of severe diseases.( In his current role, he oversees Stoke’s global commercial, medical affairs, and manufacturing functions, reflecting more than 20 years of experience guiding biopharmaceutical companies through the transition from clinical-stage to commercial-stage operations.( As a corporate insider, he has recently reported trades in Stoke Therapeutics stock in connection with his executive position.(

Prior to joining Stoke Therapeutics, Hoitt served as Chief Commercial Officer at Provention Bio, where he led pre-launch and launch strategy for Tzield® (teplizumab-mzwv), the first medicine approved to address the underlying autoimmune cause of type 1 diabetes.( He previously held the Chief Commercial Officer role at Dova Pharmaceuticals, directing launch strategy for DOPTELET® (avatrombopag) in chronic immune thrombocytopenia, and earlier was Vice President and Head of U.S. Sales at Insmed Incorporated.( Hoitt’s earlier career includes senior roles in sales, marketing and medical affairs at Sarepta Therapeutics, Vertex Pharmaceuticals, and Gilead Sciences, building a broad expertise in rare disease and specialty therapeutics.( He holds a B.A. from the College of the Holy Cross, where he studied pre‑medicine and Spanish, and has completed additional coursework in corporate finance, accounting, marketing, and organizational leadership at Columbia University.(

Written by Perplexity from public sources.